Pulmonary Hypertension Trial, Recruiting (NCT05372263)

Pulmonary Hypertension Trial, Recruiting NCT05372263 Sponsor: China National Center for Cardiovascular Diseases Condition: Pulmonary Hypertension

Printed from Voxsanity (voxsanity.com.au) — NCT05372263 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Pulmonary Hypertension

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You are between 3 months and 85 years old (any sex is welcome)
A heart procedure called a right heart catheterization has shown that the blood pressure in your lungs is high, with specific measurements meeting set thresholds (confirm with trial site)
You have been diagnosed with one of these types of pulmonary hypertension (high blood pressure in the lungs): pulmonary arterial hypertension, pulmonary hypertension linked to lung disease or low oxygen levels, pulmonary hypertension caused by blocked or narrowed pulmonary arteries, or pulmonary hypertension caused by multiple other factors
You are already taking at least one medication specifically for pulmonary hypertension, or a type of blood pressure medication called a calcium channel blocker
You are willing and able to sign a consent form agreeing to take part in the trial

Who may not be able to join:

You have been diagnosed with pulmonary hypertension that is caused by a problem with the left side of the heart

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 23 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Lu Hua, M.D, Chinese Academy of Medical Sciences, Fuwai Hospital

Phone: +86 18610094559

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05372263

Sponsor: China National Center for Cardiovascular Diseases

Phase: Not Applicable

Status: Recruiting

Condition: Pulmonary Hypertension

Trial contact: +86 18610094559

More information: https://clinicaltrials.gov/study/NCT05372263

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You are between 3 months and 85 years old (any sex is welcome)
A heart procedure called a right heart catheterization has shown that the blood pressure in your lungs is high, with specific measurements meeting set thresholds (confirm with trial site)
You have been diagnosed with one of these types of pulmonary hypertension (high blood pressure in the lungs): pulmonary arterial hypertension, pulmonary hypertension linked to lung disease or low oxygen levels, pulmonary hypertension caused by blocked or narrowed pulmonary arteries, or pulmonary hypertension caused by multiple other factors
You are already taking at least one medication specifically for pulmonary hypertension, or a type of blood pressure medication called a calcium channel blocker
You are willing and able to sign a consent form agreeing to take part in the trial

Who may not be able to join:

You have been diagnosed with pulmonary hypertension that is caused by a problem with the left side of the heart

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 23 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

China National Center for Cardiovascular Diseases

Registry

ClinicalTrials.gov

Start date

26 August 2021

Est. completion

31 August 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Adverse drug events; All-cause Mortality

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov